Lifting the Stigma: The Importance of HPV Vaccination Education in Head and Neck Cancer
June 14th 2022Tom Thomas, MD, highlights how the stigma surrounding human papillomavirus–associated head and neck cancer is being unraveled through education and the importance of vaccination as a prevention strategy.
Tislelizumab Approved By China NMPA for Recurrent or Metastatic Nasopharyngeal Cancer
June 14th 2022Based on results of the phase 3 RATIONALE-309 trial, the China National Medical Products Administration has approved tislelizumab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal cancer.
Richard Kim, MD, Discusses Key Findings With Pembrolizumab Plus Chemo in Metastatic MSS/pMMR CRC
June 13th 2022Richard Kim, MD, discussed key findings of the phase 1b KEYNOTE-651 trial, examining pembrolizumab plus standard chemotherapy in patients with microsatellite-stable or mismatch repair–proficient colorectal cancer.
Cobimetinib Plus Vemurafenib Produces Antitumor Activity in Patients With BRAF Mutations
June 7th 2022Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.